# US 2017/0283393 A1 · Bruton's Tyrosine Kinase Inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0283393 A1
- Document ID: US20170283393A1
- Status: Published application
- Kind: A1
- Application number: 15/624,969
- Filed: 2017-06-16
- Published: 2017-10-05
- Earliest claimed: 2012-11-02
- Assignees: Pfizer Inc.
- Applicants: Pfizer Inc.
- Inventors: John Robert Springer; Balekudru Devadas; Danny James Garland; Margaret Lanahan Grapperhaus; Seungil Han; Susan Landis Hockerman; Robert Owen Hughes; Eddine Saiah; Mark Edward Schnute; Shaun Raj Selness; Daniel Patrick Walker; Zhao-Kui Wan; Li Xing; Christoph Wolfgang Zapf; Michelle Ann Schmidt
- Web page: https://patentgrep.com/patent/US20170283393A1

## CPC

- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (BTK). Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the BTK inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseeases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

## Claims

### Claim 1

A compound having Formula (I)
or a pharmaceutically acceptable salt thereof, wherein
A is arylene, 5-membered heteroarylene or 6-membered heteroarylene, optionally substituted with one, two, three or four R6 independently selected from the group consisting of (C1-C4)alkyl, halo(C1-C4)alkyl, halo, hydroxy and (C1-C4)alkoxy;
X is O, S, C(═O), C(OR4) or C(R5a)(R5b);
W is aryl, 5-membered heteroaryl or 6-membered heteroaryl, optionally substituted with one, two, three, four or five R7 independently selected from the group consisting of (C1-C4)alkyl, halo(C1-C4)alkyl, (C3-C6)cycloalkyl, 4-6 membered saturated heterocycle, halo, hydroxy, hydroxy(C1-C4)alkyl, (C1-C4)alkoxy, hydroxy(C2-C4)alkoxy, and halo(C1-C4)alkoxy;
R1 is a 4-8 membered nitrogen-containing heterocyclyl substituted on said nitrogen with R and optionally further substituted with one, two, three, four or five substituents independently selected from the group consisting of (C1-C4)alkyl, halo(C1-C4)alkyl, halo, hydroxyl and (C1-C4)alkoxy;
R is cyano, cyano(C1-C3)alkyl, R or;
R2a, R2b, R3a, R3b and R4 are independently selected from the group consisting of hydrogen or (C1-C3)alkyl;
R5a and R5b are independently selected from the group consisting of hydrogen, halo and (C1-C3)alkyl;
Ra is hydrogen, halo, cyano, (C1-C6)alkoxy, halo(C1-C6)alkoxy, (C1-C4)alkylthio, (C1-C4)alkylsulfonyl, or (C1-C6)alkyl optionally substituted by halo, hydroxyl, (C1-C6)alkoxy or halo(C1-C6)alkoxy;
Rb and Rc are independently selected from the group consisting of hydrogen, halo, cyano, (C1-C6)alkoxy, halo(C1-C6)alkoxy, (C3-C6)cycloalkyl, C(═O)Rd and (C1-C6)alkyl optionally substituted with one, two or three Rf independently selected from the group consisting of halo, hydroxyl, N(Re)2, (C1-C6)alkoxy, halo(C1-C6)alkoxy and aryl; or Rb and Rc taken together with the carbon to which they are bound form a 4-7 membered carbocycyl or heterocycyl optionally substituted with one, two or three Rf independently selected from the group consisting of halo, hydroxyl, N(Re)2, (C1-C6)alkoxy; halo(C1-C6)alkoxy and aryl;
Rd is (C1-C6)alkyl, (C1-C6)alkoxy, N(Re)2 or aryl;
Re is independently selected for each occurence from the group consisting of hydrogen and (C1-C4) alkyl, or both Re taken together with the nitrogen atom to which they are bound form a 4-7 membered heterocycyl; and
G is a 5-7 membered carbocycyl or heterocycyl optionally substituted with one, two or three Rf independently selected from the group consisting of halo, hydroxyl, N(Re)2, (C1-C6)alkoxy; halo(C1-C6)alkoxy and aryl.

### Claim 2 (depends on 1)

The compound of claim 1, wherein R is cyano or cyano(C1-C3)alkyl.

### Claim 3 (depends on 1)

The compound of claim 1, wherein R is

### Claim 4 (depends on 1)

The compound of claim 1, wherein A is
and R6 is independently selected for each occurrence from the group consisting of hydrogen, (C1-C4)alkyl, halo(C1-C3)alkyl and halo.

### Claim 5 (depends on 1)

The compound of claim 1, wherein A is
and R6 is independently selected for each occurrence from the group consisting of hydrogen, (C1-C4)alkyl, halo(C1-C3)alkyl and halo.

### Claim 6

(canceled)

### Claim 7 (depends on 1)

The compound of claim 1, wherein X is O, CH2 or C(═O).

### Claim 8 (depends on 1)

The compound of claim 1, wherein X is O.

### Claim 9 (depends on 1)

The compound of claim 1, wherein X is CH2.

### Claim 10 (depends on 1)

The compound of claim 1, wherein W is phenyl optionally substituted with one, two, three, four or five R7 independently selected for each occurrence from the group consisting of (C1-C4)alkyl, halo(C1-C3)alkyl, (C1-C4)alkoxy, and halo.

### Claim 11 (depends on 10)

The compound of claim 10, wherein W is
and R7 is independently selected from the group consisting of F, Cl, methoxy and methyl.

### Claim 12 (depends on 1)

The compound of claim 1, wherein W is pyridiyl optionally substituted with one, two, three, or four R7 independently selected from the group consisting of (C1-C4)alkyl, halo(C1-C4)alkyl, halo, hydroxy, hydroxy(C1-4)alkyl, (C1-C4)alkoxy, and (C1-C4)haloalkoxy.

### Claim 13 (depends on 12)

The compound of claim 12, wherein W is
and R7 is independently selected for each occurrence from the group consisting F, Cl and CF3.

### Claim 14 (depends on 1)

The compound of claim 1, wherein R1 is
or optionally substituted with one, two, three, four or five substituents independently selected from the group consisting of (C1-C4)alkyl, halo(C1-C4)alkyl, halo, hydroxyl and (C1-C4)alkoxy.

### Claim 15 (depends on 1)

The compound of claim 1 having Formula (II)
or a pharmaceutically acceptable salt thereof, wherein
R1 is
and
W is phenyl or pyridyl, optionally substituted with one, two, three, four or five substituents independently selected from the group consisting of (C1-C4)alkyl, (C1-C3)haloalkyl and halo.

### Claim 16 (depends on 15)

The compound of claim 15, wherein W is

### Claim 17 (depends on 15)

The compound of claim 15, wherein the compound is
and pharmaceutically acceptable salts thereof.

### Claim 18 (depends on 1)

The compound of claim 1 having Formula (II)
or pharmaceutically acceptable salts thereof, wherein
R1 is
Ra is hydrogen, halo, cyano, (C1-C6)alkoxy, halo(C1-C6)alkoxy, (C1-C4)alkylthio, (C1-C4)alkylsulfonyl, or (C1-C6)alkyl optionally substituted by halo, hydroxyl, (C1-C6)alkoxy or halo(C1-C6)alkoxy;
Rb and Rc are independently selected from the group consisting of hydrogen, halo, cyano, (C1-C6)alkoxy, halo(C1-C6)alkoxy, (C3-C6)cycloalkyl, C(═O)Rd and (C1-C6)alkyl optionally substituted with one, two or three Rf independently selected from the group consisting of halo, hydroxyl, N(Re)2, (C1-C6)alkoxy and halo(C1-C6)alkoxy;
Rd is (C1-C6)alkyl, (C1-C6)alkoxy, N(Re)2 or aryl;
Re is independently selected for each occurence from the group consisting of hydrogen and (C1-C4) alkyl, or both Re taken together with the nitrogen atom to which they are bound form a 4-7 membered heterocycyl; and
W is phenyl or pyridyl, optionally substituted with one, two, three, four or five substituents independently selected from the group consisting of (C1-C4)alkyl, (C1-C3)haloalkyl and halo.

### Claim 19 (depends on 18)

The compound of claim 18, wherein W is

### Claim 20 (depends on 18)

The compound of claim 18, wherein the compound is
and pharmaceutically acceptable salts thereof.

### Claim 21 (depends on 1)

A pharmaceutical composition comprising a compound according to claim 1, or a pharmaceutically acceptable salt thereof, admixed with a pharmaceutically acceptable carrier, excipient or dilutant.

### Claim 22

(canceled)

### Claim 23 (depends on 21)

A method for treating an autoimmune disease, a heteroimmune condition or disease, an inflammatory disease, or a cancer comprising administering to a subject in need thereof a pharmaceutical composition of claim 21.

### Claim 24

(canceled)

### Claim 25

(canceled)

### Claim 26

(canceled)

### Claim 27

(canceled)

### Claim 28

(canceled)
